Designing and Molecular Modeling Studies on Novel Bisindole-imidazopyridine Against Adrenocarcinoma
Adrenocarcinoma is an uncontrolled growth of epithelial cells originating in the ducts or breast lobules. EGFR or Epidermal growth factor receptor is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. 45 bisindole-imdazopyridine analogues were obtained from the literature. Free-wilson QSAR studies were erformed on the given data set. Compounds were designed on the basis of QSAR studies. Further, Molecular docking studies were performed on the designed compounds to check the binding affinity on the protein. After that Drug-likeliness and ADMET studies were performed on the selected molecules. The results revealed that the selected analogues can be used against the treatment of adrenocarcinoma.
Keywords: Adrenocarcinoma, bisindole-imidazopyridine, QSAR, Molecular Docking, ADME studies.
2. Ignacio G. et.al. “Low and high voltage electrochemotherapy for breast cancer : an in vitro model study”. Electroporation based therapies for cancer. ScienceDirect.
3. Edridge L et.al. “Management of EGFR Positive lung cancer”. VeryWellHealth. Updated march 13, 2019.
4. Santos G.C. et.al. “EGFR Mutations and Lung Cancer”. Annual Reviews of Pathology Mechanism of Disaster. 2011. 6:49-49.
5. Reddy Dr. R. “Mechanism of Action of EGFR Mutation”. Department of respiratory medicine. Kettering hospital. Kettering. UK. Thorax 2013. Pg 68.
6. Sunkari S et.al. “Synthesis and biological evaluation of new bisindole-imidazopyridine hybride as apoptosis inducers”. Bio-organic chemistry, 21-3-19. Pg. 61
7. Ravichandran V. et.al. “Validation of QSAR models – Strategies and Importance”. International Jounal of Drug Design and Discovery. Vol 2. Issue 3. July-sept. 2011 Pg. 511-519.
8. Ye Deng et.al. “Semi-synthesis, anti-bacterial activity and molecular docking study of novel pleuromutilin derivatives bearing cinnamic acid moieties”. ArchPharm chemical life sciences. 2018.
9. Scott A et.al. “cancer cell, Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2”. Elsevier inc. april 2016.
10. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., et.al. “Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity.” J. Computational Chemistry 2009, 16: 2785-91
11. Lee SK, Chang GS, Lee IH, Chung JE, Sung KY, No KT, “The PreADME: PC-BASED PROGRAM FOR BATCH PREDICTION OF ADME PROPERTIES“, EuroQSAR 2004, 2004, 9.5-10, Istanbul, Turkey.
12. Lee SK, Lee IH, Kim HJ, G.S.Chang, J.E.Chung, K.T.No, “The PreADME Approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties“, EuroQSAR 2002 Designing Drugs and Crop Protectants: processes, problems and solutions, 2003, pp. 418-420. Blackwell Publishing, Massachusetts, USA.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).